Literature DB >> 24067421

Analysis and simulation of an Adefovir anti-hepatitis B virus infection therapy immune model with alanine aminotransferase.

Yongmei Su, Lei Zhao, Lequan Min.   

Abstract

Hepatitis B virus (HBV) infection models and anti-HBV infection therapy models have been set up to understand and explain clinical phenomena. Many of these models have been proposed based on Zeuzem et al. and Nowak et al.'s basic virus infection model (BVIM). Some references have pointed out that the basic infection reproductive number of the BVIM is biologically questionable and gave the modified models with standard mass action incidences. This study describes one anti-HBV therapy immune model with alanine aminotransferase (ALT) based on standard mass action incidences. There are two basic infection reproductive numbers R0 and R1 in the model. It is proved that if R0 < 1 and R1 < 1, the disease free equilibrium is locally and globally asymptotically stable, respectively. For the endemic equilibrium, simulation shows that if R1 > 1, it may be also globally asymptotically stable. Simulations based on clinical data of HBV DNA and ALT can explain some clinical phenomena. Simulations of the correlation between liver cells, HBV DNA, cytotoxic T lymphocytes and ALT are also given.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067421      PMCID: PMC8687198          DOI: 10.1049/iet-syb.2012.0054

Source DB:  PubMed          Journal:  IET Syst Biol        ISSN: 1751-8849            Impact factor:   1.615


  21 in total

Review 1.  Modelling viral and immune system dynamics.

Authors:  Alan S Perelson
Journal:  Nat Rev Immunol       Date:  2002-01       Impact factor: 53.106

Review 2.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

3.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

4.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

5.  Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

Authors:  G K Lau; M Tsiang; J Hou; S Yuen; W F Carman; L Zhang; C S Gibbs; S Lam
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

Review 6.  World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.

Authors:  M L Funk; D M Rosenberg; A S F Lok
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

7.  Dynamics of alanine aminotransferase during hepatitis C virus treatment.

Authors:  Ruy M Ribeiro; Jennifer Layden-Almer; Kimberly A Powers; Thomas J Layden; Alan S Perelson
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

8.  The role of cells refractory to productive infection in acute hepatitis B viral dynamics.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Patrick W Nelson; Geoffrey Dusheiko; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-14       Impact factor: 11.205

9.  Viral dynamics in hepatitis B virus infection.

Authors:  M A Nowak; S Bonhoeffer; A M Hill; R Boehme; H C Thomas; H McDade
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Modeling the mechanisms of acute hepatitis B virus infection.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Patrick W Nelson; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-03-12       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.